HSA
NRXP icon

HBK Sorce Advisory’s NRX Pharmaceuticals NRXP Stock Holding History

HBK Sorce Advisory’s Portfolio NRXP Stock Details NRXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-2,923
Closed -$13.4K – 617
2023
Q4 		$13.4K Hold
2,923
– – ﹤0.01% 564
2023
Q3 		$7.6K Hold
2,923
– – ﹤0.01% 561
2023
Q2 		$14.1K Hold
2,923
– – ﹤0.01% 580
2023
Q1 		$19.3K Sell
2,923
-2,923
-50% -$29.6K ﹤0.01% 578
2022
Q4 		$65K Buy
+5,846
New +$58.9K ﹤0.01% 710

Other funds holding NRXP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
OWMIAS
One Wealth Management Investment & Advisory Services Miami Beach, Florida $95.3M AUM 25.31% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return

HBK Sorce Advisory's NRXP Position: Q1 2024 in Review

HBK Sorce Advisory sold out of NRX Pharmaceuticals (NRXP) in Q1 2024, closing a stake of 2,923 shares — an estimated $13.4K sold.

HBK Sorce Advisory first reported a position in NRXP in Q4 2022 and held it in 5 quarters. The position peaked at $65K in Q4 2022. 31 funds tracked by Wall St. Rank hold NRXP as of Q1 2024.

  • HBK Sorce Advisory reported no remaining NRX Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • HBK Sorce Advisory sold 2,923 NRX Pharmaceuticals shares in Q1 2024, an estimated $13.4K.
  • HBK Sorce Advisory first reported a position in NRX Pharmaceuticals in Q4 2022 and held it in 5 quarters.
  • HBK Sorce Advisory's NRX Pharmaceuticals position peaked at $65K in Q4 2022.
  • 31 funds tracked by Wall St. Rank held NRX Pharmaceuticals as of Q1 2024.

Based on HBK Sorce Advisory's 13F filing for Q1 2024, filed 9 May 2024.